Speakers: 

Najma Richards, Pharmacy Intern, Geisinger Medical Center - has nothing to disclose. 

Isibelle Sienkiewcz, Pharmacy Intern, Geisinger Medical Center - has nothing to disclose. 

Courtney Turowski, Pharmacy Intern, Geisinger Medical Center - has nothing to disclose. 

Moderator: 

Sarah F. Hale, PharmD., BCPPS; Director of Pharmacy, Geisinger Medical Center - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• • Recognize the clinical significance of administering piperacillin-tazobactam as broad-spectrum antimicrobial prophylaxis for pancreatoduodenectomy.
  • Evaluate if this study warrants adjusting the standard practice for antimicrobial prophylaxis for pancreatoduodenectomy.
  • List the potential prehospital induction agents in patients with suspected severe traumatic brain injury.
  • Recognize any differences in clinical outcomes in patients who received etomidate versus ketamine.
  • Describe why patients with type 2 diabetes have a greater risk of kidney failure and cardiovascular events.
  • Explain how semaglutide impacts the primary and secondary endpoints based on the findings of the study.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD; Brain Simpkins, PharmD; Jessica Milheim, CPhT and Nichole Varela Gonzalez, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.